Free Trial

Aclaris Therapeutics (ACRS) Competitors

Aclaris Therapeutics logo
$1.61 +0.02 (+1.26%)
Closing price 04:00 PM Eastern
Extended Trading
$1.56 -0.05 (-3.11%)
As of 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ACRS vs. MRVI, IOVA, URGN, TLRY, TNGX, STOK, PRME, DNTH, PHAT, and UPB

Should you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include Maravai LifeSciences (MRVI), Iovance Biotherapeutics (IOVA), Urogen Pharma (URGN), Tilray Brands (TLRY), Tango Therapeutics (TNGX), Stoke Therapeutics (STOK), Prime Medicine (PRME), Dianthus Therapeutics (DNTH), Phathom Pharmaceuticals (PHAT), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry.

Aclaris Therapeutics vs. Its Competitors

Maravai LifeSciences (NASDAQ:MRVI) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

Maravai LifeSciences has a net margin of -67.14% compared to Aclaris Therapeutics' net margin of -732.42%. Maravai LifeSciences' return on equity of -12.91% beat Aclaris Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Maravai LifeSciences-67.14% -12.91% -6.87%
Aclaris Therapeutics -732.42%-30.73%-22.74%

Maravai LifeSciences has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500.

In the previous week, Maravai LifeSciences had 2 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 2 mentions for Maravai LifeSciences and 0 mentions for Aclaris Therapeutics. Maravai LifeSciences' average media sentiment score of 1.05 beat Aclaris Therapeutics' score of 0.68 indicating that Maravai LifeSciences is being referred to more favorably in the media.

Company Overall Sentiment
Maravai LifeSciences Positive
Aclaris Therapeutics Positive

50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 2.1% of Maravai LifeSciences shares are held by company insiders. Comparatively, 6.4% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Aclaris Therapeutics has lower revenue, but higher earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maravai LifeSciences$259.18M2.39-$144.85M-$1.14-2.13
Aclaris Therapeutics$18.72M9.31-$132.07M-$1.39-1.16

Maravai LifeSciences presently has a consensus price target of $6.64, indicating a potential upside of 173.21%. Aclaris Therapeutics has a consensus price target of $8.71, indicating a potential upside of 441.26%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aclaris Therapeutics is more favorable than Maravai LifeSciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Maravai LifeSciences
1 Sell rating(s)
7 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.25
Aclaris Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.11

Summary

Aclaris Therapeutics beats Maravai LifeSciences on 10 of the 17 factors compared between the two stocks.

Get Aclaris Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACRS vs. The Competition

MetricAclaris TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$172.17M$2.46B$5.54B$9.41B
Dividend YieldN/A1.80%3.75%4.03%
P/E Ratio-1.164.4521.0120.09
Price / Sales9.31709.89433.8199.01
Price / CashN/A164.7736.1658.27
Price / Book1.125.008.125.65
Net Income-$132.07M$30.99M$3.25B$257.91M
7 Day Performance2.55%1.69%0.97%2.09%
1 Month Performance13.38%9.20%7.36%11.13%
1 Year Performance22.90%-1.25%31.31%18.40%

Aclaris Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACRS
Aclaris Therapeutics
2.2089 of 5 stars
$1.61
+1.3%
$8.71
+441.3%
+20.5%$172.17M$18.72M-1.16100
MRVI
Maravai LifeSciences
3.5373 of 5 stars
$2.67
-2.2%
$6.64
+148.6%
-73.0%$679.94M$259.18M-2.34610Positive News
IOVA
Iovance Biotherapeutics
4.7457 of 5 stars
$2.01
+7.5%
$12.22
+508.1%
-73.8%$671.20M$164.07M-1.62500Analyst Downgrade
Analyst Revision
Gap Up
High Trading Volume
URGN
Urogen Pharma
4.337 of 5 stars
$14.49
+1.8%
$32.86
+126.8%
-8.8%$668.13M$90.40M-4.56200
TLRY
Tilray Brands
1.8639 of 5 stars
$0.66
+13.1%
$1.92
+191.8%
-67.8%$661.07M$788.94M-0.632,650
TNGX
Tango Therapeutics
1.65 of 5 stars
$6.09
+2.7%
$12.20
+100.3%
-29.7%$660.12M$40.99M-4.9990
STOK
Stoke Therapeutics
4.2311 of 5 stars
$12.06
+1.7%
$24.75
+105.2%
-9.7%$658.48M$36.56M15.27100Analyst Forecast
Gap Up
PRME
Prime Medicine
3.8285 of 5 stars
$4.80
+10.3%
$10.08
+110.1%
-38.0%$645.57M$3.85M-2.34234News Coverage
Analyst Forecast
Analyst Revision
High Trading Volume
DNTH
Dianthus Therapeutics
1.1441 of 5 stars
$20.03
-0.1%
$53.00
+164.6%
-26.5%$644.17M$6.24M-6.9580
PHAT
Phathom Pharmaceuticals
4.3042 of 5 stars
$9.06
-1.3%
$17.50
+93.2%
-31.3%$632.48M$55.25M-1.73110
UPB
Upstream Bio
1.7981 of 5 stars
$11.73
+2.2%
$56.50
+381.7%
N/A$631.00M$2.30M0.0038

Related Companies and Tools


This page (NASDAQ:ACRS) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners